• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail

Search Publications



Starting Date

Ending Date

Order by

Entry Details

Clin Transl Sci 2017 Sep;10(5):387-94

A proton pump inhibitor in the reformulation setting: bioequivalence and potential implications for long-term safety.

Dubcenco E, Beers-Block PM, Kim LP, Schotland P, Levine JG, McCloskey CA, Bashaw ED


Proton pump inhibitors (PPIs) have become known for both their therapeutic effect and good safety profile. An application was submitted to the US Food and Drug Administration for approval of a reformulated PPI product that failed bioequivalence testing, but was submitted on the basis of the long history of PPI use as a "surrogate" for equivalence. This review evaluates the safety data for PPIs, discuss variability of pharmacokinetic parameters of PPIs in the reformulation setting, and potential implications of those changes for long-term safety.

Category: Journal Article
PubMed ID: #28618191 DOI: 10.1111/cts.12475
PubMed Central ID: #PMC5593167
Includes FDA Authors from Scientific Area(s): Drugs Women's Health
Entry Created: 2017-06-18 Entry Last Modified: 2017-12-24